Twist Bioscience (NASDAQ:TWST) Price Target Raised to $40.00 at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST) had its price objective upped by JPMorgan Chase & Co. from $35.00 to $40.00 in a research report report published on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

TWST has been the subject of a number of other reports. Barclays reduced their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Scotiabank lifted their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Trading Up 0.1 %

NASDAQ:TWST opened at $53.70 on Tuesday. The firm has a fifty day simple moving average of $48.84 and a 200 day simple moving average of $46.32. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a market capitalization of $3.19 billion, a PE ratio of -14.92 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period in the previous year, the business posted ($0.75) earnings per share. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities analysts predict that Twist Bioscience will post -2.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 7,968 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $382,464.00. Following the completion of the transaction, the chief executive officer now owns 581,584 shares of the company’s stock, valued at approximately $27,916,032. The trade was a 1.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Patrick John Finn sold 10,340 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $496,320.00. Following the transaction, the chief operating officer now directly owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. The trade was a 4.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,002 shares of company stock valued at $2,851,681 over the last quarter. 3.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. ARK Investment Management LLC raised its stake in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares in the last quarter. State Street Corp raised its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Geode Capital Management LLC raised its stake in Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after acquiring an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience during the third quarter worth about $43,992,000. Finally, Wellington Management Group LLP increased its stake in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.